Rx Product News (August 2018)

AUGUST 22, 2018

BRAFTOVI WITH MEKTOVI
MANUFACTURED BY: Array Biopharma
INDICATION: The FDA has approved encorafenib (Braftovi) in conjunction with binimetinib (Mektovi) to treat patients with metastatic melanoma with BRAF V600E or BRAF V600K mutations.
DOSAGE FORM: Oral capsules and oral tablets
FOR MORE INFORMATION: braftovimektovi.com
 


ZEMDRI
MANUFACTURED BY: Achaogen
INDICATION: The FDA recently approved plazomicin (Zemdri) to treat complicated urinary tract infections, such as acute pyelonephritis, in patients when alternative treatments are ineffective or limited. Plazomicin has microbiological activity to fight off pathogens that produce enterbacteriaceae, the bacteria that causes acute pyelonephritis.
DOSAGE FORM: Intravenous injection
FOR MORE INFORMATION: zemdri.com
 

EPIDIOLEX
MANUFACTURED BY: GW Pharmaceuticals
INDICATION: Newly FDA approved cannabidiol (Epidiolex) is indicated
to treat 2 rare forms of epilepsy. Cannabidiol, the first FDA-approved drug that derives from cannabis sativa, more commonly known as marijuana, is an oral solution used to treat seizures in patients with Dravet syndrome and Lennox-Gastaut syndrome. The chemical component is purified and lacks the psychoactive element, THC, that causes euphoria or intoxication. Cannabidiol is safe for patients who are at least 2 years old.
DOSAGE FORM: Oral solution
FOR MORE INFORMATION: gwpharm.com 
 

EVERSENSE CGM
MANUFACTURED BY: Senseonics
INDICATION: The FDA approved the Eversense Continuous Glucose Monitoring (CGM) system to detect glucose levels in patients 18 and older with diabetes for up to 90 days. Eversense CGM is the first FDA- approved long-term implantable sensor to measure glucose levels, which are sent directly to an application on the patient’s cell phone every 5 minutes.
DOSAGE FORM: Implantable sensor
FOR MORE INFORMATION: eversensediabetes.com

SHARE THIS
0